[1] Mahler M, Meroni PL, Bossuyt X, Fritzler MJ Current concepts and future directions for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. J Immunol Res 2014; 315179. doi: 10.1155/2014/315179.
[2] Dellavance A, Viana VST, Leon EP, Bonfa ESDO, Andrade LEC, Leser PG The clinical spectrum of antinuclear antibodies associated with the nuclear dense fine speckled immunofluorescence pattern. J Rheumatol 2005; 32:2144–2149.
[3] Mariz HA, Sato EI, Barbosa SH, Rodrigues SH, Dellavance A, Andrade LEC Pattern on the antinuclear antibody-HEp-2 test is a critical parameter for discriminating antinuclear antibody-positive healthy individuals and patients with autoimmune rheumatic diseases. Arthritis Rheum 2011; 63:191-200.
[4] Ochs RL, Muro Y, Si Y, Ge H, Chan EK, Tan EM 2000: Autoantibodies to DFS 70 kd/transcription coactivator p75 in atopic dermatitis and other conditions. J Allergy Clin Immunol 105:1211-1220.
[5] Conrad K, Röber N, Rudolph S, Mahler M DFS70-Antikörper – Biomarker zum Ausschluss ANA-assoziierter rheumatischer Erkrankungen. J Lab Med 2014; 38: 299–307.
[6] Mahler M, Parker T, Peebles CL, Andrade LE, Swart A, Carbone Y, Ferguson DJ, Villalta D, Bizzaro N, Hanly, JG, Fritzler MJ Anti-DFS70/LEDGF antibodies are more prevalent in healthy individuals compared to patients with systemic autoimmune rheumatic diseases. J Rheumatol 2012; 39:2104-2110.